Meningococcal Vaccination in Continental Europe
Continental European countries employ diverse meningococcal vaccination strategies, but the most comprehensive approach includes MenACWY vaccination for adolescents (typically ages 11-12 years with a booster at 16-18 years) and MenB vaccination for infants, targeting the age groups and serogroups with highest disease burden. 1
Current Vaccination Landscape in Continental Europe
General Patterns Across Europe
21 European countries have implemented meningococcal vaccines in their national immunization programs (NIPs), though strategies vary considerably between neighboring countries despite similar epidemiological risks. 1
MenB is the most common disease-causing serogroup across most European countries, followed by MenW and MenC. 2
Most European countries implement MenC vaccination in infants and MenACWY vaccination in adolescents, with a growing number adding MenB vaccination for infants. 1
Specific Country Examples
Italy, Ireland, Malta, Andorra, and San Marino have the most comprehensive programs, recommending both MenB vaccination in infants and MenACWY vaccination in adolescents. 1
The Netherlands, Greece, and several other countries use various combinations of MenC (for infants/children) and MenACWY (for adolescents). 1, 2
Only Malta has introduced MenACWY vaccination in infants as part of routine immunization. 1
Recommended Schedules by Age Group
Infants and Young Children (Routine Vaccination)
For countries offering MenB vaccination in infants:
MenB vaccines (4CMenB/Bexsero) are typically administered as a 4-dose series at 2,4,6, and 12 months of age. 3
Nine European countries currently include 4CMenB in their NIP for infants: UK, Andorra, Ireland, Italy, San Marino, Lithuania, Malta, Czech Republic, and Portugal. 3
For MenC or MenACWY in infants (where implemented):
- MenACWY-TT (Nimenrix) is approved for use starting at 6 weeks of age in Europe, making it suitable for infant immunization programs. 4
Adolescents (Routine Vaccination)
Adolescents should receive MenACWY vaccination at ages 11-12 years, with a booster dose at ages 16-18 years, administered at least 8 weeks after the first dose. 5
Adolescents who receive their first dose at ages 13-15 years should receive a booster at ages 16-18 years. 5
Adolescents who receive their first dose at or after age 16 years do not require a booster dose. 5
Vaccination coverage rates are consistently higher in children than in adolescents across European countries. 2
High-Risk Individuals
For persons with persistent complement component deficiencies (C3, C5-9, properdin, factor D, factor H) or functional/anatomic asplenia:
Infants and Young Children (2-18 months):
A 4-dose primary series of MenACWY-CRM or Hib-MenCY-TT should be administered at 2,4,6, and 12 months. 5
For infants aged 9-23 months with complement deficiency, MenACWY-D can be administered as a 2-dose series at least 12 weeks apart. 5
Children ≥2 Years and Adults:
A 2-dose primary series of MenACWY (8-12 weeks apart) is recommended for individuals aged 2-55 years. 5
MenB vaccination should also be administered to high-risk individuals, with either a 2-dose series of MenB-4C (at least 1 month apart) or a 3-dose series of MenB-FHbp (at 0,1-2, and 6 months). 5, 6
Booster Doses for High-Risk Groups:
Children who receive their primary series before age 7 years should receive their first booster dose 3 years after completion, then every 5 years thereafter. 5
Children and adolescents aged ≥7 years at time of primary vaccination should receive booster doses every 5 years. 5
Other High-Risk Groups
Microbiologists routinely exposed to N. meningitidis isolates:
Should receive a single dose of MenACWY with boosters every 5 years if exposure continues. 5
Should also receive MenB vaccination (either 2-dose MenB-4C or 3-dose MenB-FHbp series). 5
Travelers to hyperendemic/epidemic areas:
Vaccination is recommended for those visiting sub-Saharan Africa's "meningitis belt" during the dry season (December-June). 5
Booster doses of MenACWY should be administered if the last dose was given ≥5 years previously. 5
Infants and children who received Hib-MenCY-TT are not protected against serogroups A and W and should receive quadrivalent meningococcal vaccination before travel. 5
Key Implementation Considerations
Vaccine Selection
Conjugate vaccines are strongly preferred over polysaccharide vaccines for all pediatric populations, as they induce immune memory and provide superior immunogenicity in young children. 5
Factors Driving Vaccination Strategies
The main determinants for implementing new vaccination strategies in European countries include:
- Fluctuating IMD epidemiology and serogroup distribution 1
- Ability to induce herd protection 1
- Ease of vaccine implementation into existing schedules 1
- Favorable benefit-risk balance and acceptable cost-effectiveness 1
- Public awareness and political will 3
Common Pitfalls to Avoid
Do not administer MenACWY-D (Menactra) to children with functional/anatomic asplenia or HIV infection before age 2 years, as it may interfere with pneumococcal conjugate vaccine (PCV) immune response. 5
- If MenACWY-D must be used in these populations, wait at least 4 weeks after completion of all PCV doses. 5
Do not assume all meningococcal vaccines are interchangeable—different manufacturers' MenB vaccines cannot be substituted for one another within a vaccination series. 7
Be aware that vaccination coverage varies significantly between countries and age groups, with adolescent coverage consistently lower than infant coverage. 2
Evidence Quality Note
The provided guidelines are primarily from American sources (AAP, ACIP) from 2007-2020, while the question specifically asks about continental Europe. The most relevant European-specific evidence comes from the 2007 FEMS Microbiology Reviews guideline 5 and recent research studies (2022-2025) describing actual European practices 1, 2, 8, 3. European countries have implemented diverse strategies that often differ from US recommendations, with no standardized pan-European approach despite similar epidemiological patterns. 1, 2